Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis

Psychological Medicine

Volumn 43, Issue 12, 2013, Pages 2571-2582

  Riecher Rossler A ^a   Rybakowski, J K ^b   Pflueger, M O ^a   Beyrau, R ^a   Kahn, R S ^c   Malik, P ^d   Fleischhacker, W W ^d  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Antipsychotic; dopamine; first episode psychosis; prolactin; schizophrenia; stress

Indexed keywords

PROLACTIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD; CLINICAL TRIAL (TOPIC); EUROPE; FEMALE; HUMAN; HYPERPROLACTINEMIA; MALE; MULTICENTER STUDY; PSYCHOSIS; SEX DIFFERENCE; YOUNG ADULT;

ADOLESCENT; ADULT; CLINICAL TRIALS AS TOPIC; EUROPE; FEMALE; HUMANS; HYPERPROLACTINEMIA; MALE; PROLACTIN; PSYCHOTIC DISORDERS; SEX FACTORS; YOUNG ADULT;

EID: 84887486949     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291713000226     Document Type: Article

References (53)

1. Akhondzadeh S, Rezaei F, Larijani B, Nejatisafa AA, Kashani L, Abbasi SH (2006). Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia. Schizophrenia Research 84, 405-410.
2. Aston J, Rechsteiner E, Bull N, Borgwardt S, Gschwandtner U, Riecher-Rössler A (2010). Hyperprolactinaemia in early psychosis - not only due to antipsychotics. Progress in Neuro-Psychopharmacology and Biological Psychiatry 34, 1342-1344.
3. Büschlen J, Berger GE, Borgwardt SJ, Aston J, Gschwandtner U, Pflueger MO, Kuster P, Radü EW, Stieglitz R-D, Riecher-Rössler A (2010). Pituitary volume increase during emerging psychosis. Schizophrenia Research 125, 41-48.
4. Bushe C, Shaw M, Peveler RC (2008). A review of the association between antipsychotic use and hyperprolactinaemia. Journal of Psychopharmacology 22, 46-55.
5. Bushe CJ, Bradley AJ, Wildgust HJ, Hodgson RE (2009). Schizophrenia and breast cancer incidence: A systematic review of clinical studies. Schizophrenia Research 114, 6-16.
6. Chong RY, Uhart M, McCaul ME, Johnson E, Wand GS (2008). Whites have a more robust hypothalamic-pituitary-Adrenal axis response to a psychological stressor than blacks. Psychoneuroendocrinology 33, 246-254.
7. Dickson RA, Seeman MV, Corenblum B (2000). Hormonal side effects in women: Typical versus atypical antipsychotic treatment. Journal of Clinical Psychiatry 61 (Suppl. 3), 10-15.
8. El Yazaji M, Battas O, Agoub M, Moussaoui D, Gutknecht C, Dalery J, d'Amato T, Saoud M (2002). Validity of the depressive dimension extracted from principal component analysis of the PANSS in drug-free patients with schizophrenia. Schizophrenia Research 56, 121-127.
9. Evans AM, Petersen JW, Sekhon GS, DeMars R (1989). Mapping of prolactin and tumor necrosis factor-beta genes on human chromosome 6p using lymphoblastoid cell deletion mutants. Somatic Cell and Molecular Genetics 15, 203-213.
10. Fitzgerald P, Dinan TG (2008). Prolactin and dopamine: What is the connection? A review article. Journal of Psychopharmacology 22, 12-19.
11. Fleischhacker WW, Keet IP, Kahn RS; EUFEST Steering Committee (2005). The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial. Schizophrenia Research 78, 147-156.
12. Garcia-Rizo C, Fernandez-Egea E, Oliveira C, Justicia A, Parellada E, Bernardo M, Kirkpatrick B (2012). Prolactin concentrations in newly diagnosed, antipsychotic-naive patients with nonaffective psychosis. Schizophrenia Research 134, 16-19.
13. Garner B, Pariante CM, Wood SJ, Velakoulis D, Phillips L, Soulsby B, Brewer WJ, Smith DJ, Dazzan P, Berger GE, Yung AR, van den Buuse M, Murray R, McGorry PD, Pantelis C (2005). Pituitary volume predicts future transition to psychosis in individuals at ultra-high risk of developing psychosis. Biological Psychiatry 58, 417-423.
14. Guest PC, Schwarz E, Krishnamurthy D, Harris LW, Leweke FM, Rothermundt M, van Beveren NJ, Spain M, Barnes A, Steiner J, Rahmoune H, Bahn S (2011). Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology 36, 1092-1096.
15. Guy W (1976). Clinical Global Impressions. In ECDEU Assessment Manual for Psychopharmacology - Revised, pp. 218-222 (DHEW publication number ADM 76-338
16. National Institute of Mental Health: Rockville, MD. Haddad PM, Wieck A (2004). Antipsychotic-induced hyperprolactinaemia: Mechanisms, clinical features and management. Drugs 64, 2291-2314.
17. Häfner H, Maurer K, Löffler W, Riecher-Rössler A (1993). The influence of age and sex on the onset and early course of schizophrenia. British Journal of Psychiatry 162, 80-86.
18. Howard L, Kirkwood G, Leese M (2007). Risk of hip fracture in patients with a history of schizophrenia. British Journal of Psychiatry 190, 129-134.
19. Howes OD, Kapur S (2009). The dopamine hypothesis of schizophrenia: Version III: - the final common pathway. Schizophrenia Bulletin 35, 549-562.
20. Hummer M, Malik P, Gasser RW, Hofer A, Kemmler G, Moncayo Naveda RC, Rettenbacher MA, Fleischhacker WW (2005). Osteoporosis in patients with schizophrenia. American Journal of Psychiatry 162, 162-167.
21. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, Lopez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE; EUFEST Study Group (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. Lancet 371, 1085-1097.
22. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261-276.
23. Kirschbaum C, Kudielka BM, Gaab J, Schommer NC, Hellhammer DH (1999). Impact of gender, menstrual cycle phase, and oral contraceptives on the activity of the hypothalamus-pituitary-Adrenal axis. Psychosomatic Medicine 61, 154-162.
24. Klomp A, Koolschijn PC, Pol HE, Kahn RS, van Haren NE (2012). Hypothalamus and pituitary volume in schizophrenia: A structural MRI study. International Journal of Neuropsychopharmacology 15, 281-288.
25. Kraepelin E (1909-1915). Psychiatry, vols 1-4 [in German].
26. Barth: Leipzig. Kretschmer E (1921). Körperbau und Charakter. Untersuchungen zum Konstitutionsproblem und zur Lehre von den Temperamenten [Physique and Character: An Investigation of the Nature of Constitution and of the Theory of Temperament]. 25th edn, 1967. Springer: Berlin, Heidelberg, New York.
27. Low WJ (2008). Neuroendocrinology. In Williams Textbook of Endocrinology (ed. H. M. Kronenberg, S. Melmed, K. S. Polonsky and P. R. Larsen), pp. 85-295. W.B. Saunders Co.: Philadelphia, PA.
28. MacMaster FP, El-Sheikh R, Upadhyaya AR, Nutche J, Rosenberg DR, Keshavan M (2007). Effect of antipsychotics on pituitary gland volume in treatment-naive first-episode schizophrenia: A pilot study. Schizophrenia Research 92, 207-210.
29. Malik P, Kemmler G, Hummer M, Riecher-Rössler A, Kahn RS, Fleischhacker WW (2011). Sexual dysfunction in first-episode schizophrenia patients: Results from European First Episode Schizophrenia Trial. Journal of Clinical Psychopharmacology 31, 274-280.
30. Miller KK (2004). Management of hyperprolactinemia in patients receiving antipsychotics. CNS Spectrums 9, 28-32.
31. Mizrahi R, Addington J, Rusjan PM, Suridjan I, Ng A, Boileau I, Pruessner JC, Remington G, Houle S, Wilson AA (2012). Increased stress-induced dopamine release in psychosis. Biological Psychiatry 71, 561-567.
32. O'Keane V, Meaney AM (2005). Antipsychotic drugs: A new risk factor for osteoporosis in young women with schizophrenia? Journal of Clinical Psychopharmacology 25, 26-31.
33. Pariante CM (2008). Pituitary volume in psychosis: The first review of the evidence. Journal of Psychopharmacology 22, 76-81.
34. Phillips LJ, McGorry PD, Garner B, Thompson KN, Pantelis C, Wood SJ, Berger G (2006). Stress, the hippocampus and the hypothalamic-pituitary-Adrenal axis: Implications for the development of psychotic disorders. Australian and New Zealand Journal of Psychiatry 40, 725-741.
35. Prabhakar VK, Davis JR (2008). Hyperprolactinaemia. Best Practice and Research: Clinical Obstetrics and Gynaecology 22, 341-353.
36. R Development Core Team (2011). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria.
37. Riecher-Rössler A, de Geyter C (2007). The forthcoming role of treatment with oestrogens in mental health. Swiss Medical Weekly 137, 565-572.
38. Riecher-Rössler A, Häfner H (1993). Schizophrenia and oestrogens - is there an association? European Archives of Psychiatry and Clinical Neuroscience 242, 323-328.
39. Riecher-Rössler A, Häfner H, Dütsch-Strobel A, Stumbaum M (1998). Gonadal function and its influence on psychopathology. Archives of Women's Mental Health 1, 15-26.
40. Riecher-Rössler A, Häfner H, Stumbaum M, Maurer K, Schmidt R (1994). Can estradiol modulate schizophrenic symptomatology? Schizophrenia Bulletin 20, 203-214.
41. Riecher-Rössler A, Kulkarni J (2011). Estrogens and gonadal function in schizophrenia and related psychoses. In Biological Basis of Sex Differences in Psychopharmacology (ed. J. C. Neill and J. Kulkarni), pp. 155-171. Springer: Heidelberg.
42. Riecher-Rössler A, Schmid C, Bleuer S, Birkhäuser M (2009). Antipsychotics and hyperpolactinaemia: Pathophysiology, clinical relevance, diagnosis and therapy [in German]. Neuropsychiatry 23, 71-83.
43. Roig B, Virgos C, Franco N, Martorell L, Valero J, Costas J, Carracedo A, Labad A, Vilella E (2007). The discoidin domain receptor 1 as a novel susceptibility gene for schizophrenia. Molecular Psychiatry 12, 833-841.
44. Rybakowski JK, Dmitrzak-Weglarz M, Kapelski P, Hauser J (2011). Functional -1149 G/T polymorphism of the prolactin gene in schizophrenia. Neuropsychobiology 65, 41-44.
45. Schwab SG, Mondabon S, Knapp M, Albus M, Hallmayer J, Borrmann-Hassenbach M, Trixler M, Gross M, Schulze TG, Rietschel M, Lerer B, Maier W, Wildenauer DB (2003). Association of tumor necrosis factor alpha gene -G308A polymorphism with schizophrenia. Schizophrenia Research 65, 19-25.
46. Segal M, Avital A, Rojas M, Hausvater N, Sandbank S, Liba D, Moguillansky L, Tal I, Weizman A (2004). Serum prolactin levels in unmedicated first-episode and recurrent schizophrenia patients: A possible marker for the disease's subtypes. Psychiatry Research 127, 227-235.
47. Stevens A, Ray D, Alansari A, Hajeer A, Thomson W, Donn R, Ollier WE, Worthington J, Davis JR (2001). Characterization of a prolactin gene polymorphism and its associations with systemic lupus erythematosus. Arthritis and Rheumatism 44, 2358-2366.
48. Tochigi M, Zhang X, Umekage T, Ohashi J, Kato C, Marui T, Otowa T, Hibino H, Otani T, Kohda K, Liu S, Kato N, Tokunaga K, Sasaki T (2004). Association of six polymorphisms of the NOTCH4 gene with schizophrenia in the Japanese population. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 128B, 37-40.
49. Ungless MA, Argilli E, Bonci A (2010). Effects of stress and aversion on dopamine neurons: Implications for addiction. Neuroscience and Biobehavioral Reviews 35, 151-156.
50. van Os J, Kenis G, Rutten BP (2010). The environment and schizophrenia. Nature 468, 203-212.
51. van Winkel R, Stefanis NC, Myin-Germeys I (2008). Psychosocial stress and psychosis. A review of the neurobiological mechanisms and the evidence for gene-stress interaction. Schizophrenia Bulletin 34, 1095-1105.
52. Walter A, Riecher-Rössler A, Studerus E, Smieskova R, Tamagni C, Rapp C, Borgwardt S (2012). Pituitary gland volume in individuals with an at-risk mental state: A longitudinal MRI analysis. Schizophrenia Research 136 (Suppl. 1), S300.
53. Yasui-Furukori N, Saito M, Nakagami T, Sugawara N, Sato Y, Tsuchimine S, Furukori H, Kaneko S (2010). Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 34, 537-540.